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The core function of a multidisciplinary team (MDT) is to bring together a group of
healthcare professionals from different fields in order to determine patients’ treatment
plan. Most of head and neck cancer (HNC) units are currently led by MDTs that at least
include ENT and maxillofacial surgeons, radiation and medical oncologists. HNC often
compromise relevant structures of the upper aerodigestive tract involving functions such
as speech, swallowing and breathing, among others. The impairment of these functions
can significantly impact patients’ quality of life and psychosocial status, and highlights
the crucial role of specialized nurses, dietitians, psycho-oncologists, social workers, and
onco-geriatricians, among others. Hence, these professionals should be integrated in
HNCMDTs. In addition, involving translational research teams should also be considered,
as it will help reducing the existing gap between basic research and the daily clinical
practice. The aim of this comprehensive review is to assess the role of the different
supportive disciplines integrated in an MDT and how they help providing a better care to
HNC patients during diagnosis, treatment and follow up.
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INTRODUCTION
A multidisciplinary team (MDT) in oncology is defined as the cooperation between different
specialized professionals involved in cancer care with the overarching goal of improving treatment
efficiency and patient care. Head and neck cancer (HNC) involves multiple and biologically distinct
diseases that require different therapeutic approaches. Patient symptoms and treatment side-effects
as well as physical and psychological impact will vary according to cancer location and treatment
plan. Joining the efforts from different professionals is thought to improve patient management in
contrast with the old idea of a global treatment offered by a single physician.
The multidisciplinary approach emerged in oncology in the mid-1980s, when the addition of
chemotherapy to radiotherapy and/or surgery was proven to improve survival. In the meantime,
organ-preservation strategies started to develop in HNC with the use of new available therapeutic
techniques (1). The MDT initially consisted in a regulated committee that reviewed all new cancer
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patients and agreed on the therapeutic plan proposed by medical
and radiation oncologist and surgical specialists based on their
clinical expertise and the evidence available to date.
When the MDT members became aware that this approach
was actually improving patient care, additional specialities
focused on supportive interventions were included in the MDTs.
The addition of the latter group of professionals improved the
quality of cancer care by preventing and diminishing treatment
side-effects, which in turn improved patient adherence and
compliance to therapies (2). The natural evolution of this
approach was the development of oncological functional units:
disease-site specific cancers focused on the management and
provision of services for cancer patients (3). These units integrate
a multidisciplinary committee and include all the departments
involved in a patient’s care with the aim of facilitating the
intervals and interactions between the different professionals,
hence reducing time to diagnosis and/or commencement
of treatment.
The first functional units created in Europe were the breast
cancer treatment units. It was not until 1998 at the First
European Breast Cancer Conference that many medical societies
focused on breast cancer treatment claimed that breast cancer
care, which includes diagnosis, treatment, genetic counseling,
psycho-social support, and research, should be assembled in
specialized units within an institution (4). This was captured
by the European Society of Breast Cancer Specialist (EUSOMA)
in the 2013 publication “the requirements of a specialist breast
center,” a consensus on the minimum requirements for the
multidisciplinary management of breast cancer in oncologic
centers (5). These guidelines were well-received by many medical
societies leading to the introduction of the multidisciplinary
approach in many countries. To date, HNC MDTs have been
successfully implemented in many countries and are now
considered standard of care for the management of HNC patients
(6). This comprehensive review evaluates the role of the different
disciplines that should be integrated in MDTs and how they
contribute to provide a better care to HNC patients during
diagnosis, treatment and follow up.
THE ROLE OF THE HNC SPECIALIZED
CLINICAL NURSE
Given its location, HNC often comes with a series of physical
and functional complexities and as such, patients will require
a comprehensive care at the bio-psycho-social level. Giving
patients full support from the time of diagnosis will be crucial
to complete the planned treatment. As an essential member
of the MDT, the role of the specialized clinical nurse in this
disease is to support patients during the whole diagnostic and
treatment process, which will include not only performing
nursing interventions (i.e., symptom, toxicity and/or wound
management) but also operational case management such as
treatment planning and coordination.
The nurse will facilitate and coordinate the activities among all
the specialists of the MDT, framing their activities in care plans
and integrating healthcare processes in collaboration with other
professionals involved in cancer care. From a patient and family
perspective, the nurse represents the anchor that will guarantee
the continuity of care throughout the entire healthcare process,
including the follow up.
At the time of diagnosis, the nurse will initially perform
a comprehensive assessment of the patient and family (or
primary caregivers). It is essential to establish a good relationship
to involve both the patient and the family in the decision-
making process and to educate them on how to prevent
and manage treatment toxicity and how to identify new
symptoms. This relationship is decisive to ensure patient
adherence and compliance to treatment and will also optimize
healthcare resources.
The role of the nurse specialist as part of the HNC MDT is
focused on three areas of action:
Case management
The case management is described as the systematic effort
to coordinate patient and family care in this complex
pathology. Methodologically, the main goal is to achieve
care results more efficiently, as it will allow a better control
of professional resources ultimately impacting on health
costs (7). The nurse applies the case management model
in the context of a specific process or disease, in this
case HNC patients within an hospital organization. One
of the nurse aims is to work with and coordinate all the
professionals that compose the MDT during the overall
process of patient care. For the patient and family, the nurse
represents the cornerstone from the diagnosis until the follow-
up and has major supportive role until the resolution of
acute toxicity. During the diagnosis and treatment planning,
the nurse controls that the appointments schedule and
required diagnostic assessments are carried out in a timely
manner to avoid unnecessary delays in starting treatment.
This is extremely important for those patients who undergo
multimodal treatment, either concurrently or sequentially (i.e.,
definitive concurrent chemo-radiation, surgery followed by
adjuvant radiation with/without chemotherapy). The nurse
will not only ensure scheduling the treatments accordingly but
will also help adapting it at every step based on each patient’s
requirements and needs.
One of the most important roles of the nurse specialist is to
offer urgent assistance to patients and families through a direct
connection during daytime (i.e., a mobile phone that allows
the patient/family to contact the nurse). This will allow the
nurse to: resolve patient questions or concerns; help managing
side-effects and symptoms; and screen for potentially severe
problems that require urgent attention and/or reference to the
emergency room. Moreover, it allows the treating physicians
to be aware of any significant event, symptom or toxicity at all
times and plan visits and/or modify treatments accordingly.
The nurse must ensure that nursing care is incorporated into
the design and implementation of clinical guidelines.
Operational role
The nurse ensures that patient referrals from primary care
or local specialists are scheduled in a timely manner to
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avoid delays, and links patients that require multimodality
treatment with the physicians from the different departments
(i.e., ENT surgical oncology, radiation oncology and/or
medical oncology).
Once the treatment decision has been made by the
HNC multidisciplinary committee, the nurse schedules an
appointment with the new patient and family/caregivers.
During this first visit, a comprehensive assessment of the
patient is conducted, which includes medical and psychosocial
status as well as support requirements. The nurse facilitates
information about the treatment, including plan and logistics,
explains the toxicity and resolves all doubts or concerns
that may appear. This visit is instrumental to consolidate
the information previously given by the specialist physician
(patient information is a key part of the quality of care).
In addition to carrying out a comprehensive and
individualized assessment, special attention is devoted to
the detection of possible alterations that may hinder the
usual treatment dynamics. This is of particular relevance in
HNC patients. Specific circuits are activated to support the
patients according to their needs: assessment of nutritional
status, swallowing and phonation, dental evaluation,
psychosocial support, rehabilitation, evaluation of toxic
habits, oncogeriatrics, and palliative care. The nursing
documentation for patient assessment is based on the
proposal according to the Functional Health Patterns defined
by Marjory Gordon (8).
Medical assistance
To provide clinical assistance is a major key role of the HNC
specialized clinical nurse. The nursing care in HNC is focused
on the following areas:
- Provide emotional support to patients and relatives after the
impact of the diagnosis and during treatment.
- Health education to patients and family members
concerning prevention, early-detection and management of
symptoms and side-effects, also providing tools to enhance
their autonomy.
- Collaboration in other healthcare areas (i.e. hospitalization,
clinical trials).
- Management of feeding tubes and gastrostomies.
- Management of tracheostomies.
- Post-surgical interventions, toxicity, and treatment-
induced dermatitis management (i.e., radiotherapy,
anti-EGFR antibodies).
DENTAL CARE FOR HNC PATIENTS
Dental attention for HNC patients is essential and must be
incorporated in each stage of the oncologic process. This process
has different and independent stages where it is important to
control the potential complications that can occur in the oral
cavity after chemotherapy and radiotherapy (9–11). Potential
toxicities and affected structures by chemotherapy, radiotherapy
and/or surgery are summarized on Table 1.
TABLE 1 | Potential outcomes of chemotherapy, radiotherapy and surgery and
the affected structures implicated.
Affected structures Potential outcomes
Skin radiation Dermatitis
Oral mucosa Mucositis
Infections: fungal, viral, bacterial
Pain
Teeth Caries caused by hyposalivation or




Muscles and soft tissues Fibrosis and trismus
Dysphagia
Speech difficulties
Temporomandibular joint Fibrosis and trismus
Tongue and taste buds Taste dysfunction
Alteration of smell Anosmia, cacosmia
Others Pain
Altered quality of life
Modified from Villa and Akintoye (12).
Any dental procedure must be avoided within chemotherapy
cycles due to the risk of complications. Chemotherapy-derived
thrombocytopenia and neutropenia can lead to hemorrhage
and infections: fungal (candidiasis), bacterial (periodontitis,
abscess, necrotic gingivitis) and viral (herpes, cytomegalovirus)
(13). Patients receiving chemotherapy, especially methotrexate,
cyclophosphamide, cisplatin, and 5-fluorouracil, can suffer
mucositis affecting the oral cavity health (14, 15). Preventive
procedures to attenuate the severity of the chemotherapy-
induced oral mucositis are: exhaustive oral hygiene, if possible,
before the chemotherapy sessions; eating soft foods; do
mouthwashes regularly when brushing the teeth (use a soft
toothbrush) using saline solution (0.9%), sodium bicarbonate
or methylcellulose; using floss in the inter-cycle stages of the
chemotherapy to avoid bleeding and reducing the microbial
load; and removal of prosthodontics (if removable) (12).
Oral cryotherapy (30-min session) is a good preventive
method in patients receiving 5-fluorouacil (12) and benzamine
hydrochloride is a positive anti-inflammatory option. Low-
level laser therapy (LLLT) or photobiomodulation has been
used with good results based on the angiogenic effect, the
stimulation on the production of serotonin, collagen and
cortisol, and improving in conjunction the synthesis of nucleic
acid (16).
Several agents can be recommended to reduce the severity
of mucositis (i.e., oral Magic mouthwash R©, a combination of
antibiotic, antihistaminic or local anesthetic, antifungal, topical
corticoid and a base that helps the other components to properly
cover the affected mucosa). Dysgeusia is commonly observed
in patients receiving chemotherapy, particularly cisplatin. It can
decrease the appetite leading to reduced oral intake and weight
loss. Zinc supplements have shown to be useful to improve the
dysgeusia in a few studies (17–19).
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Radiotherapy is the backbone of the multimodality
treatment in HNC. Given the close location of HNC to
vital anatomical structures, radiotherapy is often limited
by the risk of toxicity to the surrounding organs at risk
(20). The use of intensity modulated radiotherapy (IMRT),
which adjusts the dose to the tumor’s size, has significantly
reduced but not completely eliminated the risk of late toxicity
including xerostomia, cariës, trismus, and osteoradionecrosis
(21). The evolution of upcoming radiation modalities such
as proton-based radiotherapy with better selectivity of the
tissue to be irradiated might help reducing further these
toxicities (22, 23).
Preventive techniques to protect surrounding healthy tissue
and reduce toxicity such as xerostomia, remain controversial.
Some authors for example, prefer to use cytoprotective agents
such as amifostine (WR2721), which avoid cellular oxidation in
healthy cells (richer in alkaline phosphatase) preserving their
correct function (24, 25).
Techniques to prevent irradiation of the salivary glands
have been proposed. Auto-transplant of submandibular glands
to submental space was proposed in 2001 as an effective,
low-cost technique (26). Another proposed technique is
the application of hydrogel in the submandibular gland,
positioning it outside the irradiation area (27). Once xerostomia
is established, the chances to reverse it or improve it
significantly are low, and all the approaches are palliative,
since none of them can regenerate the salivary glands, oral
mucosa, muscular fibers, and dental tissue. A few palliative
techniques have been proposed including acupuncture, low
power laser, electrostimulation or the use of hyperbaric
oxygen, although no randomized studies have proven their
effectiveness (16, 28–30).
From a pharmacologic perspective, the administration of
parasympathomimetic agents (pilocarpine, cevimeline, and
bethanechol) has shown to improve the radiation-induced-
xerostomia in the short-midterm but not in the long-term, and
the side-effects can be a problem (31, 32). Alternative therapies
such as herbs, traditional Chinese medicine and thyme honey
have been also proposed in an attempt to improve patient quality
of life (33, 34). In any case, continued oral hydration and the use
of saliva substitutes (olive oil, betaine, or xylitol gum) are always
advisable (35).
Patients undergoing oncologic treatments for HNC must take
particular care of their oral health. Table 2 summarize dental
assessment and interventions to be performed in HNC patients
before, during and after treatment. Any dental treatment should
be preventive, if possible, because any dental treatment after the
oncologic treatments will be less effective (12, 36–38). Patients
must follow a strict oral health routine, using remineralization
elements such as fluoride. They must follow general advice such
as maintaining a balanced diet and hydric-equilibrium. Patients,
and those around them, must be aware of the acute and also
long-term treatment-related side-effects, the potential functional
and physical limitations they might encounter and the solutions
we are currently able to provide. Continued research to reduce
oral cavity toxicity and to allow the regeneration of damaged
structures, in some cases irreversibly, is needed.
TABLE 2 | Dental assessment and interventions to be performed in HNC patients
before, during, and after treatment.
Before During After





Frequent control of the
oral cavity and teeth
(every 3 months)
Teach good oral hygiene
habits


















physiotherapy (this can be
started before treatment)
After 6 months, consider
oral rehabilitation






– Evaluate the quality of life
after the treatment
Fluorine supplementation No dental intervention
required
Fluorine mouthwash
THE ROLE OF THE SPECIALIZED
DIETITIAN
Nutritional management in HNC patients is particularly
complex and face unique challenges as they are at high
risk of malnutrition due to tumor location and treatment
toxicities (39). Despite oncologic treatments have improved
both locoregional control and survival (40, 41), the acute
and long-term toxicities caused by these therapies still
compromise dietary intake contributing to significant nutritional
deterioration (42, 43).
The heterogeneity of symptoms in HNC patients due to tumor
location often overlap with local toxicity, and can all interfere
with oral intake. Hence, having the support of a specialized
dietitian within the MDT is crucial to ensure that the patient’s
nutritional status is optimized (44, 45).
The prevalence of malnutrition at diagnosis can range from
42 to 77%, and it usually worsens during treatment (46, 47).
Weight loss is one of the major concerns as more than the 85% of
patients will lose a substantial amount of weight from diagnoses
until up to 3 months after completing treatment (44). Early
nutritional assessment to optimize patient’s nutritional status and
to evaluate the need of a prophylactic feeding tube can contribute
to minimize the impact of acute toxicity, treatment interruptions
and ultimately improve survival (48).
Many studies have reported the importance of screening
malnutrition among cancer patients using different validated
tools (49–51). However, given the high prevalence of
malnutrition in HNC patients, an early complete nutritional
assessment of all patients incorporating dietetic counseling even
in those well-nourished seems to be more effective (44). Dietetic
counseling ameliorates malnutrition and reduces unplanned
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hospital admissions during treatment (52). For those patients
that are already malnourished, an early detection will help
improve their nutritional status prior to treatment and will flag
them to the treating physicians within the MDT to prioritize
and/or adjust before the start of the oncological treatment,” A
few studies have shown that an improvement in the nutritional
support prior to treatment reduces the incidence of infections,
the time of hospitalization and the severity of toxicity and leads
to improved survival (53–56).
Close nutritional monitoring during treatment is necessary to
individualize and adjust the nutritional support to the emerging
toxicity (47). At present, there is not enough evidence to
support weekly instead of bi-weekly nutritional assessments
during treatment (57) according to weight loss although weekly
assessments seem to increase adherence to the nutritional
interventions (58). Dietetic resources are usually limited;
therefore, the coordination with other health professionals may
help to improve the adherence to the nutritional support. Up
to 38% of patients do not attend the follow-up appointments
with the dietitian 4–8 weeks after treatment (57). Home visits,
telemedicine or accommodating nutritional review right before
or after the oncological evaluation may increase adherence to
visits and ultimately enhance nutrition outcomes. Nutritional
intervention in HNC patients is summarized in Figures 1A,B.
The nutritional intervention depends on multiple factors
including tumor location and stage as well as type and intent
of the oncological treatment (curative vs. palliative). In patients
undergoing surgery, the nutritional intervention aims to meet
the nutritional requirements right after the surgery trying to
return to oral intake when possible. The use of gastrostomy
feeding tube is still a matter of debate (59–63). Some studies
have shown minimize weight loss and quick return to oral intake
once the treatment is finished with the use of a nasogastric tube
when clinically indicated (62, 64). However, other authors (61,
63, 65) report the use of prophylactic gastrostomy feeding tubes
without increasing the risk of long-term swallowing dysfunction.
Recently, a systematic review reported the advantages and
disadvantages (Figure 2) of both percutaneous endoscopic
gastrostomy and nasogastric feeding tubes (66). Patients that
might require a prophylactic feeding tube prior treatment should
be assessed by the dietitian at diagnosis. The indication should
be individualized based on patient’s baseline nutritional status,
estimated time that feeding tube might be required and expected
nutritional problems during treatment. Additionally, the capacity
and characteristics of each hospital should be considered. The
final recommendation should be agreed by both the patient and
the MDT.
Sarcopenia, defined as low muscularity, has been recently
shown to be a negative prognostic factor for overall survival in
cancer patients (67). Specifically, in HNC, sarcopenia has been
correlated with an increased rate of surgical complications in
patients undergoing total laryngectomy (68) and with decreased
overall survival in those treated with either radiotherapy
alone (69) or with chemoradiotherapy (70). In addition
to the nutritional support, the implementation of physical
activity is also necessary to minimize nutritional and muscular
deterioration in HNC patients. Some studies have integrated
progressive resistance training programs during cancer treatment
showing successful patient adherence and improvement in
quality of life (71, 72).
Accumulating evidence suggests that up to 90% of HNC
patients develop acute nutrition impairment due to the
symptoms generated by the tumor location and treatment
toxicity (i.e., dysphagia, mucositis. . . ) (73, 74). Concurrent
chemoradiotherapy is associated with higher rates of toxicity
and complications when compared with surgery or radiation
alone (74). Some of the treatment toxicities can be long-
term and become chronic: swallowing dysfunction, xerostomia,
dental problems, taste alterations, and weight loss have a
significant impact on patient’s quality of life (75, 76). In
addition to the nutritional support, symptom-management
(i.e., analgesia), psycho-oncological counseling, and speech and
language rehabilitation therapy will be essential to improve their
quality of life.
A few clinical guidelines for the nutritional management of
HNC patients have been published (77, 78). These guidelines
have significantly raised awareness on the impact of nutrition
in HNC patients among oncologists and surgeons, increasing
the number of early nutritional assessments and making it
part of the treatment decision, particularly in patients with
uncertain prognosis.
PSYCHOSOCIAL SUPPORT IN HNC
PATIENTS
The diagnosis of HNC is often accompanied by difficulties in
eating, chewing, drinking, breathing, and speaking as well as by
changes in physical appearance. All these alterations can lead
to psychosocial dysfunction. There is evidence to suggest that
psychosocial interventions in these patients are effective, and as
such, clinical intervention programs should be developed as part
of their cancer care.
Psychosocial Needs
HNC patients experience profound functional and visible
changes as a result of their disease and its treatment, having
an important psychosocial impact on them and their families.
The disease and treatment toxicity result in physical and
psychological symptoms that patients must deal with, such as
dysphagia and disfigurement. Patients have problems in the
social and family setting, often related to the reduced ability
to conduct many basic functions such as eating, speaking,
and breathing. These problems can lead to limitations for
work, and also for daily activities such as driving (79).
Sometimes, it will be necessary to refer patients to a social
worker to assist them with any financial burden and facilitate
the access to the appropriate financial resources. Reduced
libido and sexual enjoyment are common in individuals
following surgery or chemoradiation. It is recommended that
the treating physicians and health care professionals address
this issue.
Cancer survivors with physical impairment or
change in appearance or function have a high risk of
Frontiers in Oncology | www.frontiersin.org 5 March 2020 | Volume 10 | Article 85
Taberna et al. The MDT Approach
A
B
FIGURE 1 | (A) Nutritional intervention in HNC patients according to the nutritional status. (B) Nutritional intervention in HNC patients according to the treatment plan.
psychosocial sequelae and diminished quality of life. This
is especially common among patients with HNC, and it
is important to help them coping with these psychosocial
aspects into their routine cancer care throughout the
illness trajectory.
Psychological Distress
No one expects to be diagnosed of cancer. Patients have to
assimilate and integrate the information about their condition
and treatment options. HNC patients suffer from the visible
nature of their disease but disfigurement and dysfunction
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FIGURE 2 | Nasogastric tube vs. percutaneous endoscopic gastrostomy: advantages and disadvantages [Extracted from Wang et al. (66)].
can often also result from surgery and radiotherapy (79). As
a consequence of these difficulties, patients can experience
depression, social anxiety, reduced self-esteem, sexual difficulties,
and a generalized sense of reduced quality of life (80, 81).
Ineffective coping strategies such as helplessness, hopelessness,
anxious preoccupation, and fatalism are strongly associated with
anxiety and depression (82). Koster and Bergsma described
HNC as more emotionally traumatic than any other type
of cancer (83). After treatment, HNC patients were more
distressed than other groups of patients. In term of coping,
they had higher levels of anxious preoccupation than other
cancer patients (84). Anxiety and depression is experienced
by ∼30–40% of patients following treatment of HNC (85,
86). One outcome of depression is suicide. Two head and
neck cancer sites alone (tongue and pharynx) accounted for
almost 20% of the total suicides among male patients with
cancer (87).
Psychological Interventions
Psychological interventions include: psychoeducational
counseling, psychotherapy (individual), cognitive behavioral
training, supportive, and group interventions. Social support is
seen as an important factor in alleviating the emotional distress
and social dysfunction experienced by patients with facial
disfigurement. Education or psychoeducation is composed by
information about the illness and treatment, coping strategies
and communication skills. Counseling or emotional support is
addressed to validate and normalize the emotional reactions,
getting an adequate emotional well-being. Psychotherapy can
be understood as a conversation process, with the objective to
change the maladaptive narrative of patients, using different
psychotherapeutic techniques. One of these psychotherapeutic
approaches, the cognitive-behavioral therapy and medication
can be considered to reduce anxious and depressive symptoms.
The most recommended psychotherapeutic approach in
cancer care is the integrative psychotherapy, which focused
in promoting alternative narratives, helping to cope the
illness and treatment. HNC support groups provide support
to patients and families by giving them the opportunity to
meet others in similar situations and learn that they are not
alone (88).
The classic risk factors associated to HNC such as tobacco
and alcohol habits need to be addressed. Similarly, the human
papilloma virus (HPV) is a new risk factor, sexually transmitted,
associated with a new profile of the HNC patient, with particular
emotional needs.
In conclusion, psychosocial impact of head and neck cancer
on patients and their families is significant. A psychological
screening intervention is an effective way to identify patients
and relatives who are at risk and might be interested
in receiving psychosocial support, improving physical, and
psychological outcomes.
THE ROLE OF THE ONCO-GERIATRICIAN
Cancer is primarily an aging associated disease. As a result of
the aging of the Western population and of a long lifetime
exposure to tobacco, alcohol and other carcinogens, HNC
in older patients is becoming a growing problem (89, 90).
Nowadays, over a half of all newly diagnosed HNCs are
in patients ≥65 years and it is estimated that in the next
decade this will increase by more than 60% (89, 90). As this
patient population is usually underrepresented in clinical trials,
data on treatment efficacy and safety is scarce, and evidence-
based guidelines are lacking (91). Due to misperceptions about
reduced survival and higher risk of toxicity in older patients,
oncologists are often reluctant to treat them with standard of
care therapies, and patients that could potentially be cured
end up receiving suboptimal treatment (92). In the overall
HNC patient population, treating physicians have to decide
the therapeutic strategy balancing the HNC-related risk of
death against the potential survival benefit from treatment.
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In the elderly, oncologists should pay particular attention to
the potential increased risk of treatment toxicity, their life
expectancy irrespective of their cancer and also their values and
goals (93, 94).
HNC in the elderly presents with a different clinical profile
when compared to younger patients: it is more frequent in
women; less associated with tobacco exposure and HPV; the
most common primary site is oral cavity and larynx, and
they usually present without nodal involvement (95). HNC are
frequently diagnosed in a locoregionally-advanced stage, and
require multimodality treatment including surgery, radiotherapy
and chemotherapy. The significant acute and late toxicities that
come with these therapies have an impact in the quality of life
of patients hence pose an extra challenge when deciding the best
treatment strategy in elderly patients with HNC (96).
Aging is a process that consists on a gradual loss of
physiologic reserves that lead to impaired function ranging
from robust health to frailty and, finally, to disability (97). Due
to the heterogeneity of the aging process, chronological age
can differ significantly from biological or functional age and
treatment decisions should not be based solely on this value
(98). Individuals who reach old age without loss of functional
capacity or severe medical conditions should be able to receive
the best therapeutic strategy according to their frailty profile.
The main challenge is how to identify the right patients for
the right treatment. Traditional tools used by oncologists to
assess functional status, such as the Eastern Cooperative Group
Performance Status (ECOG-PS) or Karnosky index (KI) have
shown to be inaccurate in this population (99, 100). The Gold
Standard to establish the frailty profile of the elderly is the
Comprehensive Geriatric Assessment (CGA). Briefly, GCA is
a multidimensional battery test that screens for impairment
in all patients and includes factors that might impact on
patient treatment tolerance and/or increased risk of toxicity:
functional status, mood, cognition, social support, nutritional
status, geriatric syndromes, polypharmacy, and comorbidity
(101) (Figure 3).
CGA helps to identify patients who are fit enough to receive
standard of care treatment, those who are vulnerable and
require an adapted treatment, and those unfit to receive any
treatment and should be managed with best supportive care
only (102, 103). In addition, CGA frequently detect geriatric
impairments missed by routine oncological clinical assessment
(104) which might be modifiable through subsequent geriatric-
based interventions (105) (Figure 4). GCA has the ability to
help decision-making by the initial frailty assessment but also
can improve treatment adherence and tolerance by developing
a tailored intervention and a supportive care plan during the
follow-up. Since CGA requires an expert physician to interpret
the results and therefore consumes time and resources, several
screening tools like Vulnerable Elders Survey (VES-13) (106)
or Geriatric-8 (G8) (107) have been developed to distinguish
fit patients who are able to receive standard treatment from
those who need a wider geriatric evaluation (108–110). Given
the accumulating evidence supporting the role of CGA for
clinical decision making, the main international societies and
guidelines recommended CGA in patients aged 70 years or
FIGURE 3 | Domains evaluated in Comprehensive Geriatric Assessment
(CGA).
older before making a decision on cancer treatment (111–113).
Most studies assessing the relevance of CGA have been done in
cancer patients with different tumor types but the information
among HNC is scarce (114). The on-going EGeSOR study is
currently evaluating the impact of a multidimensional geriatric
intervention based on CGA on outcome in elderly patients with
HNC (NCT02025062) (115).
However, the optimal treatment should be decided
considering both geriatric and oncological variables trying
to find the proper balance between the tumor stage, the expected
treatment benefit and toxicity and its potential impact on quality
of life as well as the increased risk of toxicity and expected overall
survival in the elderly. Based on this information, patients with
a same geriatric profile might be considered fit enough to be
treated with single-modality but not with a multi-modality
treatment. That is why a CGA by an onco-geriatrician should be
part of the HNC MDT (116). Recently, the ELAN-ONCOVAL
(Elderly head and Neck Cancer-Oncology eValuation) study
evaluating the use of a suited geriatric evaluation to stratify
patients and guide therapy in patients ≤70 years old not
amenable to surgery showed that, despite the initially planned
treatment was changed only in 8% of the cases after a geriatric
assessment, the number of patients requiring multidisciplinary
interventions was significantly higher when the assessment
was performed by geriatrician (71 vs. 51%) (117). The results
of this study highlight the relevance of incorporating the
onco-geriatrician in the decision making process for the elderly.
Multimodality treatment in HNC is associated with significant
acute and long-term toxicity and represents an additional
challenge in the elderly. Most of the studies evaluating therapy
according to age in HNC patients did not show significant
differences in survival between young and elderly patients
(118). Nevertheless, older patients may experience greater
Frontiers in Oncology | www.frontiersin.org 8 March 2020 | Volume 10 | Article 85
Taberna et al. The MDT Approach
FIGURE 4 | Algorithm for treatment decision making in older patients with HNC.
treatment-related toxicity, specifically with higher intensity
treatments (94). When evaluating the outcome of single
modality treatments such as surgery or radiotherapy, no
differences were seen between younger and older patients
(119). Importantly, postsurgical complications, or toxicity
rates were not influenced by chronological age. While the
survival benefit from chemotherapy remained similar across
age, older patients had higher rates of toxicity (nephrotoxicity,
diarrhea, and thrombocytopenia) (119). The results regarding
concomitant chemoradiotherapy are controversial, likely
due to heterogeneous populations (120, 121). However, a
study comparing elderly patients receiving radiotherapy alone
vs. multimodality therapy, showed that patients from the
multimodality group had similar survival rates to younger
patients, while those treated with radiation alone had strikingly
inferior outcome (122). The use of targeted therapies such as
cetuximab is common in the elderly because they are perceived
to be less toxic than platinum-based chemotherapy, but no
prospective studies have compared the safety profiles in this
specific patient population (91). As regards the use of immune-
checkpoint inhibitors in the elderly, the trials conducted thus far
do not seem to suggest that higher toxicity should be expected
in this subgroup of patients (123). Based on this data, we
can conclude that a subgroup of fit older patients can benefit
from aggressive therapy, being comorbidity and functional age
better predictors of treatment tolerance and efficacy rather than
chronological age (124–126).
In summary, older patients with HNC require an “age-
friendly” healthcare model based on “case management.” An
individualized comprehensive assessment of the elderly patients
leads to a more accurate treatment decision leading to a more
efficient use of the healthcare resources. A specialized geriatric
assessment of elderly HNC patients is crucial to drive the
optimal oncological treatment strategy and as such, it should be
integrated within the MDT.
THE ROLE OF THE SPEECH AND
LANGUAGE PATHOLOGY EXPERT
Patients who have undergone a total laryngectomy (TL) will
inevitably have to face a wide range of sequelae that will have a
considerable impact on their quality of life.
From the speech and language pathology (SLP) perspective,
themost obvious and limiting handicap is the loss of the laryngeal
voice and, consequently, of the person’s ability to communicate
orally in the same way as they did until the moment of the
surgery. The voice, in addition to the basic instrument for human
communication, is for everyone a hallmark of self-identity (127)
and reveals aspects such as personality traits, mood or gender.
Inability to speak, or to do it with a “new voice” totally
different from the one that has been “the own voice” during a
person’s life, involves very important changes in that person’s
daily life, and can significantly impact on his/her social and
familiar relationships, ultimately leading to anxiety, depression,
and alterations in self-esteem and self-image (128).
Vocal Rehabilitation
Vocal rehabilitation in patients treated with a TL to restore
oral communication requires a process of adaptation and
readjustment to this new voice that is crucial in order to
improve and restore their quality of life (129). After the surgery,
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FIGURE 5 | Voice after a total laryngectomy. Vocal rehabilitation alternatives after total removal of the larynx Images courtesy of Atos medical.
patient can be taught laryngeal techniques by an SLP expert
through an intensive and structured work. The alternatives of
communication after the TL, are:
- Esophageal speech
TL results in a permanent separation of the airway and digestive
tract. In the absence of the larynx, a patient can learn to generate
a new sound—laryngeal voice- through the vibration generated
by the air passing through the pharyngo-esophageal segment.
This fundamental frequency will be articulated in the oral cavity,
generating different phonemes or speech sounds.
In the esophageal speech, the air is injected or inhaled from
the oral or nasal cavity, to the upper esophageal sphincter,
and immediately returned to the oral articulatory structures.
The learning process of the esophageal speech can be long
and requires an intensive, guided and structured work. Hence
setting realistic goals in the short term will be important to
prevent demotivation. It is also necessary to systematically
evaluate patient’s progress during the therapy in order to identify
difficulties that could make this strategy impossible, and adapt it
to patient possibilities.
- Tracheoesophageal speech (voice prosthesis)
The tracheoesophaigeal speech is obtained after a surgical
procedure which consists of the generation of a fistula in the
posterior wall of the trachea, where a voice prosthesis is placed.
A voice prosthesis (VP) is a cylindrical, silicone device that has
a one-way valve mechanism that allows the passage of expiratory
air flow from the trachea to the neoglottis. Airflow through the
esophageal structure will generate a new fundamental tone that,
as with the esophageal voice, will later be converted into speech
sounds. The use of a voice prosthesis for communication requires
daily maintenance and needs to be replaced approximately every
6months, (130–132) The rate of complications can range from 15
to 72% (132), being the most frequent the leak through de voice
prosthesis and the leak around the tracheoesophageal prosthesis.
The involvement of the speech pathologist to train how to
manage these complications is important in order to prevent
and to minimize their impact, and is also required to provide
a continuous follow-up in the rehabilitation process until
stabilization. A proper follow-up by an SLP expert of patients
with phonatory prostheses is associated with better overall results
in their rehabilitation (133).
Compared with esophageal speech, tracheoesophageal speech
has demonstrated better results in some voice analysis parameters
such as fundamental frequency, maximum phonation time,
intensity and other aspects as speech intelligibility (134). Some
studies found a correlation between the use of a VP, with a
positive restoration of quality of life, self-esteem, and sexual
function, with the consequent decrease in the symptoms of
depression and anxiety (135).
- Electrolarynx
The electrolarynx is an external device with a sound-head cap
that, when activated and in contact with the skin, generates a
vibration, usually monotonal, which is transmitted to the oral
cavity. To speak with an electrolarynx, the patient has to press
a button and move his mouth to articulate different sounds. This
system can be very useful to facilitate immediate communication
during the hospitalization period, as communication through
esophageal speech or VP is not possible as it requires training.
When voice alternatives fail, electrolarynx is an excellent solution
to allow oral communication.
Overall, the best communication system is the one that will
provide the best results according to patient communicative
needs and expectations. Ideally, the laryngectomized patient
could develop more than one communication strategy, such as
a combination of an esophageal voice and the tracheoesophageal
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TABLE 3 | Areas of focus in SLP interventions.
Pre-surgery phase
Goals Solve all doubts that may arise to the patient and their relatives,
related to what their life will be like, from the anatomical,
physiological and functional point of view, after TL.
Provide information regarding potential sequelae, such as vocal,
pulmonary, eating and olfaction sequelaes. Information about
their treatment and the existing devices to reduce the impact
and preserve their quality of life, such as cannulas, adhesives,
free hands devices for speech among others.
Explain and show communication alternatives available.
Promote contact with another person who has already been
rehabilitated or, when appropriate, provide audiovisual materials
with real examples of similar cases of patients that satisfactorily
overcome their illness and rehabilitation process.
Evaluation of vocal rehabilitation possibilities of the patient.
Evaluate phonatory, respiratory, swallowing and olfactory
patterns, to adjust an adequate prophylactic program if
necessary, and determine realistic goals for rehabilitation
according to the needs, expectations and commitment of the
patient.
Design a prophylactic program of pre-surgical exercises,
according to time, treatment, and patient feasibility.
Structure the therapeutic work plan after surgery, agreed
between the patient and their SLP.
Post-surgery phase
Goals Fitting the proper system to help the patient for communication
during hospitalization.
Global evaluation to determine how is the starting point for
rehabilitation, in terms of mood, communicative intention,
scarring, fistulas, nasogastric tube, dysphagia, skin condition,
configuration of the stoma, volume and characteristics of the
secretions, voice prosthesis, weight, muscle tone…
First adaptation of the rehabilitation devices.
Review and start of the therapeutic work plan established in the
pre-operative evaluation.
Follow-up phase
Goals Permanent review of concepts and doubts that the patient and
or family may have.
Prevention of difficulties associated with the use of rehabilitation
devices through training in the proper use of it, and the
understanding of the warning signs that the patient should
inform to the professional.
Promotion of patients’ self-care regarding rehabilitation and
management of the rehabilitation devices.
Checking of the evolution of the established therapeutic goals.
Upon discharge, providing the patient with an easily accessible
SLP contact.
Intervention of the expert SLP on main sequelae groups: voice, pulmonary, eating and
olfaction. TL, total laryngectomy; SLP, speech and language pathologist’.
voice, as they can easily coexist (Figure 5). This will allow the
patient to choose themost appropriate option to speak depending
on the communicative context. Table 3 summarizes pre and
post-surgical SLP recommended interventions.
In order to guide and individualize the rehabilitation therapy,
many variables need to be considered: the type of surgery,
adjuvant treatments, patient psycho-social status and cultural
environment, motor and visual skills, communicative needs,
and patient’s motivation. Furthermore, speech therapy protocols
should not be developed in isolation. The accumulated evidence
to date and the available clinical guidelines support the idea that
a multidisciplinary approach of a patient with a TL, leads to a
greater and better overall therapeutic success, and facilitates the
restoration of an optimal level of quality of life (129). Thus, the
work of the SLP should be integrated into a well-structured MDT
that guarantee a good information flow among professionals who
are specialists in the different related areas (136).
In addition to the diagnostic impact, HNC patients must face
the concern on how their life might change after treatment.
Research and clinical experience highlight the benefits of an early
involvement of an SLP expert in the treatment of TL patients who
suffer voice alteration, as well as a longitudinal follow up until
rehabilitation discharge.
Providing information, support, and solving issues related
to sequelae will facilitate a better quality of care and greater
therapeutic success, which in turn will have a positive impact on
the primary purpose of the multidisciplinary approach; restore as
much as possible, the quality of life of our HNC patients.
THE CLINICAL AND TRANSLATIONAL
RESEARCH IN HNC PATIENTS
Head and neck MDT and HNC units have been shown to be
an effective tool to facilitate collaboration between professionals
and hence improve care outcomes. This concept is accepted
worldwide as the “gold standard” of cancer care (137).
Although MDTs are the central component of cancer care in
many countries, there is a notable gap regarding how clinical and
translational research can be integrated into these teams. Several
publications involving multiple cancer types have described the
importance ofMDTs and oncological functional units to facilitate
the smooth cooperation between cancer care professionals and
improve patient cancer care. However, none of them discussed
the potential benefits of incorporating the translational research
teams within these units (6, 138).
We believe that clinical and translational research should
be integrated within the HNC units. The prognosis of HNC
patients remains guarded with a 5-year survival rate of 50% (139).
The implementation of clinical trials provides an opportunity
to offer more effective and less toxic treatment options in these
patients. As HNC management is multidisciplinary, involving
the different MDT professionals in the development of clinical
trials is essential to design more accurate studies, especially
in the locoregionally-advanced setting. The management of
recurrent/metastatic disease is often complex and also requires
multidisciplinary evaluation. Adapting the diagnostic and
treatment circuits to facilitate the screening assessments required
for clinical trials in this setting such as biopsies will avoid delays
in the commencement of treatment and the successful patient
enrolment in these studies.
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Additionally, the integration of translational research teams
in tumor boards and MDTs can help reducing the existing gap
between current clinical practice and basic research. The input
that basic researchers can receive from clinicians might be useful
to guide translational projects. The reciprocal interaction and
feedback from researchers and physicians will also contribute
to improve prospective studies and determine the feasibility of
the correlative analysis. The success of a translational project
involving patient care is based on the coordination of the
team. Tumor biopsies and collection of other specimens such
as saliva, blood or stool are currently requested by prospective
clinical and also correlative studies. Therefore, the collaboration
and the timely coordination between research laboratories
and clinics are crucial to conduct these studies smoothly
and successfully.
Proposed recommendations to succeed in the integration of
clinical and translational research within the MDT and HNC
units are:
- Elect a coordinator for clinical and translational research
within the unit.
- Promote periodic meetings to update projects and explain
novel proposals.
- Make it open to all members of the unit so that everyone can
contribute with new ideas and lead projects.
- Include educational programs to young members and trainees.
- Create working groups to distribute projects with appointed
project leaders among the MDT members.
CONCLUSION
MDTs and oncologic functional units significantly improve the
quality of cancer care. The integration of all the departments
and professionals involved in the treatment of a specific
cancer guarantees full and continued support to patients during
diagnosis, treatment and follow-up periods and it is perceived
positively by most patients. The different members of an MDT
will provide close management of symptoms and acute/long-
term side effects; adequate nutritional support, psychosocial
reinforcement, and individualized follow-up. A comprehensive
assessment andmonitoring of HNCpatients by specializedMDTs
will result in better treatment adherence and tolerance, reduction
in long-term side effects, improved quality of life and ultimately
improved treatment outcome and survival.
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